Trending: Moderna's Proposed RSV Vaccine Faces Delayed FDA Review
Provided by
Dow Jones
13:53 ET -- Moderna is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The company said that the U.S. Food and Drug Administration won't meet the target action date of May 12 for a decision on its proposed vaccine for respiratory syncytial virus, or RSV. Moderna said the FDA cited administrative constraints for the delay and is working to complete its review by the end of the month, adding that the agency hasn't flagged any issues that would prevent an approval. Dow Jones & Co. owns Factiva. (zaeem.shoaib@wsj.com)
(END) Dow Jones Newswires
May 10, 2024 14:08 ET (18:08 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
3 Cheap and Dependable Dividend-Growth Stocks to Buy
-
The Best Bank Stocks to Buy
-
After Earnings, Is Roblox Stock a Buy, Sell, or Fairly Valued?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?